Some hypotheses have been proposed to elucidate this clinical representation, including cross-reactivity between SARS-CoV-2 and pituitary proteins, COVID-19-associated coagulopathy, infection-driven acutely increased pituitary blood demand, as well as anti-platelet factor 4/heparin antibody progress after vaccination [26]. This evidence concerns the gene PF4 and COVID-19.